title: The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective.
abstract: OBJECTIVE
  To evaluate the cost-effectiveness of an extended (12+12 weeks) course of varenicline plus brief counselling compared with the currently reimbursed smoking cessation interventions (in combination with brief counselling) in Belgium, from a public payer perspective.
  
  
  METHODS
  The previously published version of the BENESCO model which included the extended course of varenicline was updated with recent publically available demographic and cost data from Belgium.
  
  
  RESULTS
  The extended course of varenicline plus brief counselling has an incremental cost per quality adjusted life year gained of 1101€ compared with a nonextended 12-week course of varenicline (plus brief counselling). The extended course of varenicline dominates all other comparators in this analysis.
  
  
  CONCLUSIONS
  The extended course of varenicline (12 weeks followed by 12 weeks maintenance therapy in successful quitters) plus brief counselling is a highly cost-effective alternative to a non-extended (12 weeks only) course of varenicline plus brief counselling. This strategy dominates the other alternative smoking cessation interventions currently reimbursed in Belgium.
authors: HERON Evidence Development Ltd., Luton, UK. chris.knight@heronhealth.com
authors: C
authors: C
authors: Knight
authors: S
authors: S
authors: Marbaix
authors: L
authors: L
authors: Annemans
authors: J
authors: J
authors: Prignot
authors: K
authors: K
authors: Bowrin
mesh_terms: D000328:Adult; D001530:Belgium / Q000453:epidemiology; D001552:Benzazepines / Q000191:economics* / Q000627:therapeutic use*; D016642:Bupropion / Q000191:economics / Q000627:therapeutic use; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D003376:Counseling / Q000191:economics*; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D008297:Male; D018722:Nicotinic Agonists / Q000191:economics* / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D011810:Quinoxalines / Q000191:economics* / Q000627:therapeutic use*; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods*; D016896:Treatment Outcome; D000068580:Varenicline
chemical_list: D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D000068580:Varenicline